Why the study?
Does recombinant human superoxide dismutase enhance the pulmonary vascular effects of inhaled nitric oxide in a newborn lamb model of persistent pulmonary hypertension?
Does recombinant human superoxide dismutase enhance the pulmonary vascular effects of inhaled nitric oxide in a newborn lamb model of persistent pulmonary hypertension?
Recombinant human superoxide dismutase reduces pulmonary vascular resistance and enhances the vasodilatory effects of inhaled nitric oxide in a lamb model of persistent pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for rhSOD-iNO synergy in PPHN; prospective human trials required before any clinical consideration.
We investigated the pulmonary vascular effects of superoxide dismutase (SOD) alone and in combination with inhaled nitric oxide (iNO) in newborn lambs with persistent pulmonary hypertension (PPHN) following prenatal ligation of the ductus arteriosus. In in vitro experiments, pretreatment with SOD significantly enhanced vascular relaxation in response to the NO donor S-nitrosyl-acetylpenicillamine (SNAP) in fifth-generation pulmonary arteries isolated from lambs with PPHN. In vivo treatment of fully instrumented newborn lambs with a single intratracheal dose of recombinant human CuZn SOD (rhSOD; 5 mg/kg) produced selective dilation of the pulmonary circulation. Further studies, of the combination of rhSOD and iNO, showed enhancement of the pulmonary vascular effects of iNO after brief periods of inhalation of 5 ppm and 80 ppm NO. We conclude that rhSOD reduces pulmonary vascular resistance and facilitates the action of iNO in a lamb model of PPHN. This suggests that rhSOD may prove to be an effective adjunctive treatment for newborns with PPHN.
No takes yet. Share an insight, caveat, or question.
Steinhorn et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: